近年以来,随着多家企业布局和管线持续推进,眼科药物市场的内卷开始显现。“近视神药”或将迎来“双王”争霸赛。1月2日晚间,兆科眼科(06622.HK)发布公告称,国家药品监督管理局(下称“国家药监局”)已受理公司核心产品之一、用于治疗儿童近视加深的NVK002(低剂量阿托品0.01%)的简化新药申请。此项简化新药申请乃以其在中国的第III期临床试验结果为基础。根据2024年10月23日披露的公告,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.